Ultra-wide-field Fluorescein Angiography in Patients With Macular Edema Secondary to Retinal Vein Occlusion

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

RECRUITING

Total Enrollment

60 participants

Study Classification

OBSERVATIONAL

Study Start Date

2023-10-09

Study Completion Date

2025-12-15

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

This study mainly observed the ischemic index and vascular leakage index changes on ultra-wide field fluorescence angiography after anti-VEGF treatment , and whether these changes correlated with treatment efficacy in patients with macular edema secondary to retinal vein occlusion.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Ranibizumab Treatment for Macular Edema Secondary to Retinal Vein Occlusion

NCT04062370

Retinal Vein Occlusion Treatment Photocoagulation Burn to Retina +1 more

UNKNOWN PHASE4

Anti-VEGF in Real-world

NCT05222633

Neovascular Age-related Macular Edema Diabetic Macular Edema Choroidal Neovascular Membrane +3 more

UNKNOWN

Predictive Factors of Ranibizumab Treatment in Macular Edema With CRVO

NCT02091505

Central Retinal Vein Occlusion

UNKNOWN NA

Change Oxygen Consumption Following Intravitreal Treatment of Lucentis (Ranibizumab) in Eyes With Diabetic Macular Edema

NCT02329132

Diabetic Macular Edema

COMPLETED

Ranibizumab (Lucentis) for Macular Edema Secondary to Vein Occlusions

NCT00407355

Macular Edema Retinal Vein Occlusion

COMPLETED PHASE1/PHASE2

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Ultra-wide field fluorescence angiography can clearly observe the peripheral retina. This study mainly observes the ischemic index and vascular leakage index changes on UWFA after anti-VEGF treatment and evaluates these changes associated with treatment efficacy in patients with macular edema secondary to retinal vein occlusion.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Retinal Vein Occlusion Macular Edema

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

COHORT

Study Time Perspective

PROSPECTIVE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

UWFA-RVO-ME

Ultra-wide-field fundus fluorescein angiography on patients with macular edema secondary to retinal vein occlusion treated with Ranibizumab

Ranibizumab 0.5 MG/0.05 ML Intraocular Solution [LUCENTIS]

Intervention Type DRUG

Intravitreal injection of Ranibizumab 0.5 MG/0.05 ML

Ultra-wide Fluorescein Angiography

Intervention Type DEVICE

Ultra-wide-field Fluorescein Angiography can clearly observe the peripheral retina

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Ranibizumab 0.5 MG/0.05 ML Intraocular Solution [LUCENTIS]

Intravitreal injection of Ranibizumab 0.5 MG/0.05 ML

Intervention Type DRUG

Ultra-wide Fluorescein Angiography

Ultra-wide-field Fluorescein Angiography can clearly observe the peripheral retina

Intervention Type DEVICE

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

Lucentis Anti-VEGF

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

1. Male or female aged 18 years or older
2. Macular edema secondary to CRVO,BRVO or HRVO
3. Duration of RVO not more than 4 months
4. Naïve patients. Patient with previous RVO (more than 12 months before the inclusion date) completely resolved (normalization of visual acuity and fundus examination) and who have experienced a recurrence of RVO are also considered naive
5. Patient who agrees to participate in the study and who has given his/her written, informed consent

Exclusion Criteria

1. Patient with another retinal disease in the study eye: diabetic retinopathy, maculopathy of any cause (age-related macular degeneration, epimacular membrane, myopia, etc) responsible for decreased vision, advanced glaucoma, cataract severely affecting vision and/or requiring surgical treatment during the 24 months study period
2. Active or suspected ocular or periocular infection
3. Active severe intraocular inflammation
4. RVO complicated with neovascularization
5. Patient who has previously undergone laser panretinal photocoagulation, grid-laser or photodynamic therapy, any anti-VEGF or corticoids intravitreal injections in the study eye
6. Patient already included in the study for the treatment of the fellow eye
7. Pregnant or breastfeeding woman
8. Lack of effective contraception for women of childbearing age
9. Patient taking part in an interventional study

Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No